Clortermine hydrochloride (Voranil) is a non-amphetamine anorexigenic agent. Voranil, a sympathomimetic amine, is indicated for short-term adjunctive treatment of exogenous obesity. Its long duration of action permits once-a-day dosage. In a large number of patients studied, Voranil was found to be superior to placebo in weight reduction. Insomnia, dry mouth, palpitations and tachycardia have been reported in a small percentage of patients taking the drug. Voranil was originally developed by Ciba Pharmaceuticals Corporation and transferred to USV Pharmaceuticals Corporation in December 1971, as a result of a product exchange agreement. In most patients a single 50 mg/day oral dose was prescribed.

Excerpt from NCATS:
https://drugs.ncats.io/drug/4FA88HM3IX

Clortermine (Voranil) is an anorectic drug of the amphetamine class. It is the 2-chloro analogue of the better known appetite suppressant phentermine, and is the 2-chloro positional isomer of chlorphentermine. Clortermine produces very low rates of self-administration in animals similarly to chlorphentermine, and as a result it likely does not act on dopamine. Instead, it may act as a serotonin and/or norepinephrine releasing agent.

Excerpt from MedKoo:
https://www.medkoo.com/products/29542

Clortermine:

• An anorectic drug of the amphetamine class
• Developed by Ciba in the 1960s
• Its an analogue of the better known appetite suppressant phentermine and is the 2-chloro positional isomer of chlorphentermine

Similarly to chlorphentermine it likely does not act on dopamine. Instead, it may act as a serotonin and/or norepinephrine releasing agent.